US2022010295A1PendingUtilityA1

Subtilase variants and polynucleotides encoding same

Assignee: NOVOZYMES ASPriority: Jun 18, 2015Filed: Sep 29, 2021Published: Jan 13, 2022
Est. expiryJun 18, 2035(~8.9 yrs left)· nominal 20-yr term from priority
C11D 3/386C12N 9/54C12Y 304/21062
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to subtilase variants suitable for use in, e.g., cleaning or detergent compositions, such as laundry detergent compositions and dish wash compositions, including automatic dish wash compositions. The present invention also relates to isolated DNA sequences encoding the variants, expression vectors, host cells, and methods for producing and using the variants of the invention.

Claims

exact text as granted — not AI-modified
1 . A subtilase variant comprising a set of alterations selected from the group consisting of:
 (a) X167A+R170S+A194P and one or more substitutions selected from the group consisting of X59D, X62D, X76D, X104T, X120D, X133P, X141N, X156D, X163G, X209W, X228V, X230V, X238E, X261D, and X262E;   (b) *99aE and one or more substitutions selected from the group consisting of X21D, X59D, X101H, X120D, X156D, X163G, X194P, X195E, X209W, X238E, X256D, X261D, and X262E;   (c) X62D and one or more substitutions selected from the group consisting of X101H, X104T, X156D, X163G, X170S, X170L, X209W, X238E, X245R and X262E;   (d) X62D+X245R+X248D and one or more substitutions selected from the group consisting of X156D, X163G, X163K, X170S, X209W, and X262E;   (e) X170L, X170N or X170S and one or more substitutions selected from the group consisting of X57P, X167A, X172E, X206E,   (f) X99D and one or more substitutions selected from the group consisting of *97aN, *98aA, X98T, X261D, and X262Q, wherein   (i) the positions correspond to the positions of the polypeptide of SEQ ID NO: 2;   (ii) the variant has protease activity; and   (iii) the variant has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1 or 2.   
     
     
         2 . The subtilase variant according to  claim 1 , which comprises the substitutions X167A+X170S+X194P and one or more substitutions selected from the group consisting of X59D, X62D, X76D, X104T, X120D, X133P, X141N, X156D, X163G, X209W, X228V, X230V, X238E, X261D, and X262E. 
     
     
         3 . The subtilase variant according to  claim 1 , which comprises the alteration *99aE and one or more substitutions selected from the group consisting of X21D, X59D, X101H, X120D, X156D, X163G, X194P, X195E, X209W, X238E, X256D, X261D, and X262E. 
     
     
         4 . The subtilase variant according to  claim 1 , which comprises the substitution X62D and one or more substitutions selected from the group consisting of X101H, X104T, X156D, X163G, X170S, X170L, X209W, X238E, X245R and X262E. 
     
     
         5 . The subtilase variant according to  claim 1 , which comprises the substitutions X62D+X245R+X248D and one or more substitutions selected from the group consisting of X156D, X163G, X163K, X170S, X209W, and X262E. 
     
     
         6 . The subtilase variant according to  claim 1 , which comprises the substitutions X170L, X170N or X170S and one or more substitutions selected from the group consisting of X57P, X167A, X172E, X206E. 
     
     
         7 . The subtilase variant according to  claim 1 , which comprises the substitution X99D and one or more alterations selected from the group consisting of *97aN, *98aA, X261D, and X262Q. 
     
     
         8 . The subtilase variant according to any of  claim 1 , which further comprises one or more alterations selected from the group consisting of X3T, X4I, X9C, X9D, X9E, X9Q, X14T, X24G, X24R, X27R,*36D, X43A, X43C, X43L, X43R, X43W, X68A, X72A, X72V, X76D, X78D, X87R, X87S,*97E, X98S, X99A, X99D, X99A, X99D, X99E, X99G,*99aD, X101D, X101E, X101G, X101I, X101K, X101L, X101M, X101N, X101R, X103A, X104F, X104I, X104N, X104Y, X106A, X114V, X115T, X115W, X118R, X118V, X120D, X120I, X120N, X120T, X120V, X123S, X128A, X128L, X128S, X129D, X129N, X129Q, X130A, X147W, X149C, X149N, X158E, X160D, X160P, X161C, X161E, X162L, X163A, X163D, X182C, X182E, X185C, X185E, X188C, X188D, X188E, X191N, X195E, X199M, X204D, X204V, X205I, X206C, X206E, X206I, X206K, X206L, X206T, X206V, X206W, X209W, X212A, X212D, X212G, X212N, X216I, X216T, X216V, X217C, X217D, X217E, X217M, X217Q, X217Y, X218D, X218E, X218T, X222C, X222R, X222S, X225A, X232V, X235L, X236H, X245K, X245R, X252K, X255C, X255E, X256A, X256C, X256D, X256V X256Y, X259D, X260E, X260P, X261C, X261E, X261F, X261L, X261M, X261V, X261W, X261Y, X262C, X262E, X262Q, and X274A, wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2. 
     
     
         9 . The subtilase variant according to  claim 1 , comprising or consisting of a set of alterations selected from the group consisting of:
 *99aE+A194P   N76D+Y167A+R170S+A194P   N76D+Y167A+R170S+A194P+A228V+A230V   99aE+S256D   L21D+*99aE   N62D+Q245R+R170S   R170L+Q206E+S57P   A133P+Y167A+R170S+A194P   S141N+Y167A+R170S+A194P   Y167A+R170N   Y167A+R170S+A172E   N62D+Y167A+R170S+A194P   N62D+R170S   N62D+R170L   97aN+A98T+S99D   98aA+S99D+N261D+L262Q   Q59D+N76D+Y167A+R170S+A194P;   Q59D+*99aE+Y209W+L262E;   Q59D+Y167A+R170S+A194P+Y209W+L262E;   Q59D+Y167A+R170S+A194P+L262E;   N62D+S101H+R170S+Y209W+L262E;   N62D+V104T+S156D+R170S+Y209W+L262E;   N62D+V104T+R170S+Y209W+L262E;   N62D+S156D+S163G+Y209W+Q245R+N248D+L262E;   N62D+S156D+S163G+Y209W+L262E;   N62D+S156D+S163K+Y209W+Q245R+N248D+L262E;   N62D+S156D+R170S+Y209W+L262E;   N62D+R170S+Y209W+Q245R+N248D+L262E;   N62D+R170S+Y209W+L262E;   N62D+R170S+N238E+L262E;   N76D+Y167A+R170S+A194P+N238E;   *99aE+S101H+H120D+S163G+N261D;   *99aE+S156D+Y209W+L262E;   *99aE+B194P+G195E+Y209W+L262E;   *99aE+B194P+G195E+L262E;   *99aE+N238E+L262E;   V104T+H120D+S163G+Y167A+R170S+A194P+N261D;   V104T+S156D+Y167A+R170S+A194P+Y209W+L262E;   V104T+Y167A+R170S+A194P+Y209W+N238E+L262E; and   V104T+Y167A+R170S+A194P+N238E+L262E.   
     
     
         10 . The subtilase variant according to  claim 1 , which is a variant of subtilisin 309 (SEQ ID NO: 1), comprising or consisting of the set of alterations. 
     
     
         11 . The subtilase variant according to  claim 1 , which is a variant of subtilisin BPN′ (SEQ ID NO: 2), comprising or consisting of the set of alterations. 
     
     
         12 . The subtilase variant according to  claim 1 , which has an improved wash performance compared to SEQ ID NO: 1 when measured in AMSA assay. 
     
     
         13 . The subtilase variant according to  claim 1 , wherein the total number of alterations compared to SEQ ID NO: 1 is between 3 and 30. 
     
     
         14 . A method for producing a subtilase variant of  claim 1 , comprising
 (a) introducing into a parent subtilase a set of alterations selected from the group consisting of:   (1) X167A+R170S+A194P and one or more substitutions selected from the group consisting of X59D, X62D, X76D, X104T, X120D, X133P, X141N, X156D, X163G, X209W, X228V, X230V, X238E, X261D, and X262E;   (2) *99aE and one or more substitutions selected from the group consisting of X21D, X59D, X101H, X120D, X156D, X163G, X194P, X195E, X209W, X238E, X256D, X261D, and X262E;   (3) X62D and one or more substitutions selected from the group consisting of X101H, X104T, X156D, X163G, X170S, X170L, X209W, X238E, X245R and X262E;   (4) X62D+X245R+X248D and one or more substitutions selected from the group consisting of X156D, X163G, X163K, X170S, X209W, and X262E;   (5) X170L, X170N or X170S and one or more substitutions selected from the group consisting of X57P, X167A, X172E, X206E,   (6) X99D and one or more substitutions selected from the group consisting of *97aN, *98aA, X98T, X261D, and X262Q;   wherein   (i) the positions correspond to the positions of the polypeptide of SEQ ID NO: 2;   (ii) the variant has protease activity; and   (iii) the variant has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1 or 2.   (b) recovering the variant.   
     
     
         15 . The subtilase variant of  claim 8 , which comprises Y209W. 
     
     
         16 . The subtilase variant of  claim 8 , which comprises L262E.

Join the waitlist — get patent alerts

Track US2022010295A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.